Outpatient CLABSIs costly for pediatric stem cell transplant and oncology patient populationNews-Medical.netPediatric stem cell transplant and cancer patients often are discharged from the hospital with an external central venous line for medications t… Continue reading
Wall Street JournalStem-Cell Treatments Become More Available, and Face More …Wall Street JournalIn two days of hearings next month, the U.S. Food and Drug Administration will consider if clinics offering stem-cell treatments should be more closely r… Continue reading
Wall Street Journal |
Stem Cell Treatment Promised by Clinics, but Has It Been Proven?
Wall Street Journal Nearly 600 clinics in the U.S. are touting stem–cell therapies to combat everything from “aging” to autism and Alzheimer’s disease. While stem–cell research is booming, mainstream scientists say it will be years before such therapies are proven safe … Stem Cell Therapies – Clinical Advancement, Driving Growth, Still Represents a Significant Challenges: Global Trends …Medgadget (blog) $27-million awards to fast-track stem cell researchLaboratory Products News |
|
Stem Cell Therapies – Clinical Advancement, Driving Growth, Still Represents a Significant Challenges: Global Trends …
Medgadget (blog) MrrBiz614 Recent research and the current scenario as well as future market potential of “Stem Cell Therapies – Global Trends In The Competitive, Technological And R&D Landscape” globally. MarketResearchReports.Biz Research’s latest report, “”Stem … $27-million awards to fast-track stem cell researchLaboratory Products News |
|
As Leukemia Evolves, Stem Cells Hold Keys to Newer Therapies
University of Rochester Newsroom But Becker’s study breaks new ground by showing that as the disease progresses, leukemia stem cells (the root of the disease) change and often begin expressing additional proteins that weren’t present when the cancer first occurred or lose protein … |
FierceBiotech |
Picking Up The Pieces In Stem Cell Therapy
Seeking Alpha Anyone with the fixed idea that stem cells are of no use in heart failure would have found little to dissuade them in two presentations at the European Society of Cardiology meeting in Rome on Sunday. Celyad’s (OTC:CLYYF) phase III trial Chart-1 was … CardioCell stem cells ‘improve well-being’ of heart failure patientsFierceBiotech CardioCell Reports Positive Results From the First Phase IIa Clinical Trial Using IV Administration of Stem Cells …PR Newswire (press release) |